On April 21, 2025, Eyal Rubin, Sr. Vice President and Chief Financial Officer of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), provided the Company and the Company’s Board of Directors with six months’ notice of his resignation from his position with the Company and its subsidiary, in order to pursue other opportunities.
Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board
On April 21, 2025, the Board of Directors (the “Board”) of Nova LifeStyle, Inc. (the “Company”) received a resignation letter from Ms. Thanh H. Lam to resign from her positions as the Chief Executive Officer (“CEO”) and President of the Company, effective immediately.
In connection with this transition, the Company appointed Eric A. Mendelson and Victor H. Mendelson to serve as Co-Chief Executive Officers (co-principal executive officers), also effective May 1, 2025.
In connection with this transition, the Company appointed Eric A. Mendelson and Victor H. Mendelson to serve as Co-Chief Executive Officers (co-principal executive officers), also effective May 1, 2025.
Appointed
Robert Rajalingam
Chief Executive Officer
PATTERSON COMPANIES, INC.
Effective
2025-04-17
Filed
April 22, 2025, 7:59 PM ET
Robert Rajalingam was appointed as the new Chief Executive Officer of the Company effective April 17, 2025.
Departed
Donald Zurbay
Chief Executive Officer
PATTERSON COMPANIES, INC.
Effective
2025-04-17
Successor
Robert Rajalingam
Filed
April 22, 2025, 7:59 PM ET
Donald Zurbay, who previously served as Chief Executive Officer and a director of the Company, ceased to serve in such roles effective the same day.
Departed
(interim)
Thomas Langan
Interim Chief Executive Officer
Veradigm Inc.
Effective
2025-07-31
Filed
April 22, 2025, 7:59 PM ET
Thomas Langan, the Company’s Interim Chief Executive Officer, President and Chief Commercial Officer, entered into a Separation Agreement (the “Langan Separation Agreement”), pursuant to which Mr. Langan’s employment with the Company will terminate effective July 31, 2025
Appointed
Bradley Herring
Executive Vice President and Chief Financial Officer
On April 22, 2025, the Board of Directors (“Board”) of OPENLANE, Inc. (the “Company”) appointed Bradley Herring as Executive Vice President and Chief Financial Officer of the Company, effective May 27, 2025.
On April 22, 2025, Weatherford International plc (the “Company”) announced the appointment of Anuj Dhruv, 43, to serve as the Company’s Executive Vice President and Chief Financial Officer, effective April 21, 2025.
Departed
Arunava Mitra
Executive Vice President and Chief Financial Officer
In conjunction with the appointment of Mr. Dhruv, Arunava Mitra has left Weatherford effective April 21, 2025 and has ceased to serve as its Executive Vice President and Chief Financial Officer.
Effective May 1, 2025, Jessica Betjemann will begin service as an Executive Vice President and the Company’s CFO.
Departed
Chadi Chahine
Chief Financial Officer and EVP of Supply Chain Operations
Paragon 28, Inc.
Effective
2025-04-21
Filed
April 21, 2025, 7:59 PM ET
On April 17, 2025, Chadi Chahine delivered a letter of resignation to the Company and Parent to notify the Company and Parent of his decision to resign as Chief Financial Officer and EVP of Supply Chain Operations of the Company, effective upon the consummation of the Merger.
Appointed
(interim)
Bob Finley
Interim Chief Financial Officer
Medicine Man Technologies, Inc.
Effective
2025-04-21
Filed
April 21, 2025, 7:59 PM ET
On April 15, 2025, Medicine Man Technologies, Inc. (the “Company”) retained Bob Finley, a partner at FLG Partners, LLC (“FLG Partners”), a chief financial officer services and board advisory consulting firm, as the Company’s Interim Chief Financial Officer (principal financial officer and principal accounting officer).
On April 18, 2025, the Board of Directors of the Company appointed Chen Franco-Yehuda, age 41, to serve as the Company’s Chief Financial Officer, Treasurer and Secretary, effective as of May 15, 2025.
On April 18, 2025, Mr. Zvi Ben-David resigned as Chief Financial Officer, Treasurer and Secretary of DarioHealth Corp. (the “Company”), effective as of May 15, 2025.
Appointed
Alan Campion
Chief Financial Officer
CHIMERIX INC
Effective
2025-04-21
Filed
April 21, 2025, 7:59 PM ET
the officers of the Company are as follows: Alan Campion, Chief Financial Officer, and Andrea Burke, Vice President.
On April 15, 2025, Mr. Vecchione notified the Company’s Board of Directors of his ability to return from his temporary leave of absence and upon such notification, the Board of Directors acted to reappoint Mr. Vecchione to the offices of President and Chief Executive Officer of the Company, effective as of April 15, 2025.
Appointment of Chief Financial Officer On April 21, 2025, Appian Corporation (the “Company”) issued a press release announcing that Srdjan “Serge” Tanjga has been appointed Chief Financial Officer of the Company, effective May 27, 2025 (the “Effective Date”).
On April 21, 2025, MongoDB, Inc. (the “Company”) announced that Srdjan (“Serge”) Tanjga , the Company’s Interim Chief Financial Officer, and the Company’s principal financial officer under Section 16a-1(f) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), has notified the Company of his intent to resign from his position , effective May 8, 2025.
Role change
Michael Jansen
Chief Financial Officer
Titan Environmental Solutions Inc.
Effective
2025-04-15
Successor
Anna Skowron
Filed
April 21, 2025, 7:59 PM ET
On April 15, 2025, the Company terminated Michael Jansen as the Company’s Chief Financial Officer.
Appointed
Anna Skowron
Chief Financial Officer and Secretary
Titan Environmental Solutions Inc.
Effective
2025-04-15
Filed
April 21, 2025, 7:59 PM ET
On April 15, 2025, Titan Environmental Solutions Inc. (the “ Company ”) appointed Anna Skowron as the Company’s Chief Financial Officer and Secretary, effective immediately.
Peter Salzmann, M.D. retired from his roles as the Chief Executive Officer and principal executive officer of Immunovant, Inc. (the "Company" or "Immunovant"), effective April 20, 2025
Also effective April 20, 2025, Renee Barnett ceased serving as the Chief Financial Officer (including the principal financial officer and principal accounting officer) of the Company.
Jost Fisher will step down as Interim President and Chief Executive Officer but will continue to serve as chairman of the Board, a member of the audit committee and chair of the compensation committee.
Appointed
Robert Bancroft
Chief Executive Officer, President and Principal Executive Officer
On April 19, 2025, the board of directors (the “Board”) of AEON BioPharma, Inc. (the “Company”) appointed Robert Bancroft, age 60, as the Company’s Principal Executive Officer, President, Chief Executive Officer and member of the Board to serve as a Class I director, effective as of April 29, 2025.
When Mr. Shigemura exits his current role, his duties as CFO will be assumed by current Senior Executive Vice President and Deputy CFO Bradley S. Satenberg.
Appointed
Brian Baker
Chief Financial Officer
DYNATRONICS CORP
Effective
2025-05-09
Filed
April 18, 2025, 7:59 PM ET
In connection with Mr. Ellwein's resignation, the Company's Board of Directors has appointed Brian Baker as Chief Financial Officer (principal financial officer and principal accounting officer) of the Company, effective as of May 9, 2025.
Departed
Gabe Ellwein
Chief Financial Officer
DYNATRONICS CORP
Effective
2025-05-09
Successor
Brian Baker
Filed
April 18, 2025, 7:59 PM ET
On April 15, 2025 Gabe Ellwein informed Dynatronics Corporation (the "Company") of his decision to resign as Chief Financial Officer (principal financial officer and principal accounting officer) of the Company, effective as of May 9, 2025, to pursue other professional interests.
On April 18, 2025, the Board of Directors of Two Harbors Investment Corp. (the “Company”) confirmed that William Dellal has been designated as the Company’s Vice President and Chief Financial Officer and will serve in such role until further notice.
On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.
On April 18, 2025, Michael C. Greiner announced that he will leave Avanos Medical, Inc. (the “Company”) to pursue other opportunities because the Company did not offer him a position comparable to the one he held prior to his role as the Company’s Interim Chief Executive Officer.
On April 17, 2025, Spirit Aviation Holdings, Inc. (“Spirit” or the “Company”) announced the appointment of David Davis as President, Chief Executive Officer of the Company and as a member of the Board of Directors of the Company (the “Board”), in each case to be effective April 21, 2025.
On April 17, 2025, CRH public limited company (‘CRH’ or the ‘Company’) announced the appointment of Nancy Buese as Chief Financial Officer, effective as of May 12, 2025.
Todd L. Capitani, the Company’s current Chief Financial Officer, who previously announced his retirement, will continue with the Company until August 15, 2025 to support this leadership transition.
Appointed
Charles S. Cullum
Executive Vice President and Chief Financial Officer
On April 17, 2025 , Shore Bancshares, Inc. (the “Company”) announced that it appointed Charles S. Cullum to Executive Vice President and Chief Financial Officer effective April 21, 2025.
The disclosures set forth in Item 1.01 regarding Norman E. Snyder’s retirement and resignation from the positions of Chief Executive Officer and director and the terms of the Transition Agreement are incorporated into this section (b) by this reference.
The disclosures set forth in Item 1.01 regarding Cyril Wallace’s appointment as Chief Executive Officer and the terms of the Employment Agreement are incorporated into this section (c) by this reference.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.